Buprenorphine Hydrochloride, 0.3mg/mL recall — Endo Usa, Inc. (Class II)

Endo Usa, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Buprenorphine Hydrochloride, 0.3mg/mL — a Class II recall, initiated 2026-03-13 and posted to the FDA enforcement report on 2026-05-20, under recall number D-0527-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Crystallization; identified as Buprenorphine free base”. From the product description, the form is injection, the strength given is 0.3mg/mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 42023-179-05. Distribution is recorded as “USA Nationwide” — Nationwide (US), with the recalling firm on record in MI, United States. It is the only recall number the FDA has filed under event ID 98610. 68 days separate the firm's initiation date from the FDA's report date on this record. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0527-2026
FDA event ID 98610
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Endo Usa, Inc.
Recall initiated 2026-03-13
Reported by FDA 2026-05-20
Report lag 68 days from initiation to report
Distribution USA Nationwide — Nationwide (US)
Firm location on record MI, United States
Product description (source) Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.

Reason reported by FDA

Crystallization; identified as Buprenorphine free base

6 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 20-word product description above; each is a literal substring of it.

Product named Buprenorphine Hydrochloride
Form Injection
Strength 0.3mg/mL
NDC 42023-179-05
Marketing category Rx only
Manufactured for Endo USA, Malvern

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Oasis Tears PF, 10mLD-0525-2026Oasis Medical, Inc.Class II2026-05-20
Ascend Laboratories, 25 mgD-0547-2026Ascend Laboratories, LLCClass II2026-05-20
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 20 mgD-0516-2026Ajanta Pharma Ltd.Class II2026-05-13
BD PurPrep, 8.3%D-0517-2026Carefusion 213, LLCClass II2026-05-13

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-20 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
BD PurPrep, 8.3%D-0518-2026Carefusion 213, LLC8.3% · Solution2026-05-13
Octreotide Acetate for Injectable Suspension, 30 mgD-0519-2026Teva Pharmaceuticals Usa, Inc30 mg · Injectable Suspension2026-05-13
Enalapril Maleate Tablets, 20 mgD-0520-2026JB Chemicals And Pharmaceuticals Ltd20 mg · Tablets2026-05-13
Duloxetine Delayed-Release Capsules USP, 60mgD-0522-2026Breckenridge Pharmaceutical, Inc.60mg · Delayed-Release Capsules2026-05-13
NAPROXEN ORAL SUSPENSION, 125 mg/5mLD-0523-2026Acella Pharmaceuticals, LLC125 mg/5mL · Oral Suspension2026-05-13
TPN bag (patient specific), 1660 mLD-0524-2026Central Admixture Pharmacy Services, Inc (caps) Los Angeles1660 mL · Injection2026-05-13
Atomoxetine Capsules HCL, 10 mgD-0538-2026Safecor Health, LLC10 mg · Capsules2026-05-27
Liraglutide Injection, 18 mg/3 mLD-0541-2026Lupin Pharmaceuticals Inc.18 mg/3 mL · Injection2026-05-27

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 42023-179-05 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Endo Usa, Inc. (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0527-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0527-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-20
Ingested
2026-08-22
Record hash
93bff770466bb8d6

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.